Skip to main content
Fig. 2 | Journal for ImmunoTherapy of Cancer

Fig. 2

From: Antibody targeting tumor-derived soluble NKG2D ligand sMIC provides dual co-stimulation of CD8 T cells and enables sMIC+ tumors respond to PD1/PD-L1 blockade therapy

Fig. 2

Combination therapy of sMIC-targeting mAb B10G5 and anti-PD-L1 antibody cooperatively enhances anti-tumor potential of CD8+ T cells. a and c, Representative dot plots and summary data from all animals present that cocktail therapy significantly enriched CD8 T cell in draining LN (dLN) and tumor infiltrates. b and d, Representative histograms (c) and summary data (d) of CD8 T cell IFNγ production in response to SV40TAg re-stimulation. e and g, Representative histograms (e) and summary data (f) of CD44Hi CD8 T cell population. f and h. Representative histograms (g) and summary data (h) of IFNγ production by CD44Hi CD8 T cells in response to PMA/ionomycin stimulation. Spln, spleen. dLN, tumor-draining lymph node, TIL, tumor infiltrated lymphocytes. ns, not significant

Back to article page